COLL - Collegium Pharmaceutical: Changing My Strategy After Q3 Earnings Beat

Summary

• My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat has forced me to update my strategy.
• Collegium's new products from the BDSI acquisition have already helped the company report record revenue. In addition, the company's Xtampza ER will have an improved gross-to-net starting January 1st.
• Collegium continues to manage its finances by paying down its debt, while also supporting a share repurchase program.
• The ticker still has some risks to consider. I give COLL a conviction rating of 3 out of 5.
• I reveal my strategy to restart my accumulation of COLL.

For further details see: